161807-18-7

Basic information

• Product Name: (6-Chloro-pyridin-2-yl)-acetic acid methyl ester
• Synonyms: (6-Chloro-pyridin-2-yl)-acetic acid methyl ester;6-Chloro-2-pyridineacetic acid Methyl ester;Methyl 2-(6-chloropyridin-2-yl)
• CAS NO: 161807-18-7
• Molecular Formula: C₈H₈ClNO₂
• Molecular Weight: 185.60762
• Mol File: 161807-18-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 251.7±25.0 °C(Predicted)
• Appearance: /
• Density: 1.259±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -0.45±0.10(Predicted)
• CAS DataBase Reference: (6-Chloro-pyridin-2-yl)-acetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (6-Chloro-pyridin-2-yl)-acetic acid methyl ester(161807-18-7)
• EPA Substance Registry System: (6-Chloro-pyridin-2-yl)-acetic acid methyl ester(161807-18-7)

Safety Data

• Hazardous Substances Data: 161807-18-7(Hazardous Substances Data)

Usage

General Description

"(6-Chloro-pyridin-2-yl)-acetic acid methyl ester" is a chemical compound that belongs to the class of organic compounds known as pyridines and derivatives. Pyridines are compounds containing a pyridine ring, a six-membered aromatic heterocycle, in which one carbon atom is replaced by a nitrogen atom. The precise physical properties of this compound, such as its appearance, boiling point, melting point, etc., may vary. However, this compound is of interest in a variety of chemical research and applications. As is common with many organic compounds, it should be handled with care to prevent potential hazards or risks.

Upstream product

• 18368-63-3 6-chloro-2-picoline 
• 616-38-6 carbonic acid dimethyl ester 
• 67-56-1 methanol 
• 75279-60-6 2-(6-chloropyridin-2-yl)acetonitrile 
• 885267-14-1 2-(6-chloropyridin-2-yl)acetic acid 

Downstream Products

• 1355052-41-3 C₂₀H₁₆FNO₃ 
• 947381-33-1 methyl 3-phenylindolizine-1-carboxylate 
• 947381-06-8 methyl 5-chloro-3-phenylindolizine-1-carboxylate 

Relevant articles and documents

TRIAZOLONE COMPOUNDS AND USES THEREOF

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

TRIAZOLE DERIVATIVE OR SALT THEREOF

[Problem] To provide a compound which may be used in treating diseases in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is concerned, especially diabetes and insulin resistance. [Means for Solution] It was found that a triazole derivative or a pharmaceutically acceptable salt thereof, in which the 3-position of triazole ring is substituted with a trisubstituted methyl group and the 5-position is substituted with a lower alkyl, cycloalkyl or the like, has a strong 11β-HSD1-inhibitory activity. In addition, since the triazole derivative of the present invention shows excellent blood glucose-lowering action, it may be used in the treatment of diabetes and insulin resistance.

Catalytic asymmetric cyclopropanation of heteroaryldiazoacetates

Rh2(S-DOSP)4-catalyzed decomposition of heteroaryldiazoacetates in the presence of styrene results in highly diastereoselective and enantioselective cyclopropanations. Heteroaryldiazoacetates containing both electron-rich and electron-deficient heterocycles, such as thiophene, furan, pyridine, indole, oxazole, isoxazole, and benzoxazole, are effective in this chemistry. These studies broaden the range of diazo compounds containing both electron-withdrawing and electron-donating groups, which undergo highly diastereoselective cyclopropanations.